Storme Guy A
Department Radiation Oncology, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.
Cancers (Basel). 2023 Apr 8;15(8):2205. doi: 10.3390/cancers15082205.
Breast cancer treatment has seen tremendous progress since the early 1980s, with the first findings of new chemotherapy and hormone therapies. Screening started in the same period.
A review of population data (SEER and the literature) shows an increase in recurrence-free survival until 2000 and it stagnates afterwards.
Over the period 1980-2000, the 15% survival gain was presented by pharma as a contribution of new molecules. The contribution of screening during that same period was not implemented by them, although screening has been accepted as a routine procedure in the States since the 1980s and everywhere else since 2000.
Interpretation of breast cancer outcome has largely focused on drugs, whereas other factors, such as screening, prevention, biologics, and genetics, were largely neglected. More attention should now be paid to examining the strategy based on realistic global data.
自20世纪80年代初发现新的化疗和激素疗法以来,乳腺癌治疗取得了巨大进展。同期开始了筛查。
对人口数据(监测、流行病学与最终结果项目及文献)的回顾显示,无复发生存率在2000年之前有所上升,之后停滞不前。
在1980 - 2000年期间,制药公司将15%的生存率提高归功于新分子。同期筛查的贡献未被他们认可,尽管自20世纪80年代起筛查在美国已成为常规程序,自2000年起在其他各地也成为常规程序。
对乳腺癌治疗结果的解读主要集中在药物上,而其他因素,如筛查、预防、生物制剂和遗传学,在很大程度上被忽视了。现在应更加关注基于实际全球数据审视治疗策略。